Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2021 16:08 ET | Source: Genmab A/S

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; February 26, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 123,949 restricted stock units to four members of management...
February 25, 2021 14:53 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; February 26, 2021 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
February 23, 2021 11:05 ET | Source: Genmab A/S

Genmab announces initiation of share buy-back program

Company Announcement Repurchase of up to 200,000 sharesMitigating dilution from warrant exercises and honoring commitments under our Restricted Stock Unit programCompletion expected no later than...
February 23, 2021 11:00 ET | Source: Genmab A/S

Genmab Publishes 2020 Annual Report

Company Announcement Copenhagen, Denmark; February 23, 2021 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2020. Below is a summary of business progress in...
February 22, 2021 08:00 ET | Source: Genmab A/S

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of...
February 10, 2021 16:05 ET | Source: Genmab A/S

Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

Company Announcement Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark and BOTHELL,...
January 29, 2021 12:10 ET | Source: Genmab A/S

CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis

Company Announcement Novartis receives positive CHMP opinion for subcutaneous ofatumumab for adult patients with relapsing forms of multiple sclerosis Opinion based on Phase 3 ASCLEPIOS I and II...
January 28, 2021 16:56 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 28, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 4,457 restricted stock units and 14,220...
January 27, 2021 09:50 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; January 27, 2021 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses...
January 26, 2021 06:45 ET | Source: Genmab A/S

Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)

Company Announcement Net sales of DARZALEX® in 2020 totaled USD 4,190 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 26, 2021 –...